Clinical trial · Observational
Immunotherapy in Lung Cancer: Treatment After IO Cessation.
Immunotherapy in Lung Cancer: Which Treatment After Immunotherapy Cessation: A Prospective Registry From the European Lung Cancer Working Party
NCT04465942CI-TRIAL-00053440unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Immunotherapy is now a standard of care for first-line and eventually salvage therapy in patients with stage IV NSCLC and as adjuvant after RT-CT for stage III NSCLC. The aim of the study is determining the therapeutic landscape and the reason for immunotherapy cessation.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Non-Small-Cell Lung | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
| Immunotherapy | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| (chemo)immunotherapy | Drug | Immunotherapy | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- to determine the therapeutic landscape after cessation of an immune checkpoint therapy
- timeFrame
- From IO cessation date up to first treatment whatever the time in-between and up to 5 years
- description
- Which treatment is proposed after IO cessation
Secondary outcomes (7)
- measure
- survival
- timeFrame
- From IO cessation date up to death or up to 5 years
- description
- survival after ICI cessation, overall and in pre-defined subgroups (cessation for progressive disease \[group 1\], for toxicity \[group 2\], by patient decision without progression \[group 3\])
- measure
- Activity of salvage therapy - response
- timeFrame
- At the end of cycle 2 or 3 (according to routine local practice), one cycle corresponding to 21 days, up to 6 cycles. assessment will done according to RECIST criteria
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histological diagnosis of non-small cell lung cancer (NSCLC) * Stage IVA/IVB and unresectable and non irradiable stage III NSCLC naïve of immunotherapy. * Patients who receive immunotherapy (any type) monotherapy, combined immunotherapy or in combination with chemotherapy for first or second-line treatment. * Availability for participating in the detailed follow-up of the protocol. * Signed informed consent. Exclusion Criteria: * Patients receiving adjuvant immunotherapy for stage I-III NSCLC are not eligible * Tumours for which TNM stage at time of study inclusion cannot be assessed. * History of prior malignant tumour, except non-melanoma skin cancer or in situ carcinoma of the cervix or of the bladder or cured malignant tumor (more than 5-year disease free interval). * Any type of immunotherapy for previous cancer
References
Publications (0)
Data not yet available
No reference posted for this study.